April 26, 2017 — The National Comprehensive Cancer Network (NCCN) continues to build its NCCN Radiation Therapy Compendium with the publication of radiation therapy (RT) recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):
The new guidelines include recommendations for:
- Acute Lymphoblastic Leukemia, Version 2.2016;
- Basal Cell Skin Cancer, Version 1.2017;
- Dermatofibrosarcoma Protuberans, Version 1.2017;
- Gastric Cancer, Version 1.2017;
- Hodgkin Lymphoma, Version 1.2017;
- Merkel Cell Carcinoma, Version 1.2017;
- Ovarian Cancer, Version 1.2017;
- Squamous Cell Skin Cancer, Version 1.2017; and
- Thymomas and Thymic Carcinomas, Version 1.2017.
Launched in March 2017, the NCCN Radiation Therapy Compendium now includes recommendations from 33 NCCN Guidelines. Additional cancer types will be published on a rolling basis over the coming months.
The compendium provides guidance on all RT modalities recommended within the NCCN Guidelines, including:
- Intensity modulated radiation therapy (IMRT);
- Intra-operative radiation therapy (IORT);
- Stereotactic radiosurgery (SRS)/stereotactic body radiotherapy (SBRT)/stereotactic ablative radiotherapy (SABR);
- Image-guided radiotherapy (IGRT);
- Low dose-rate brachytherapy (LDR)/High dose-rate brachytherapy (HDR);
- Radioisotope; and
- Particle therapy.
Transparency of NCCN Guidelines and Compendia development is central to the philosophy, policies and procedures of NCCN. NCCN posts the policies and processes for developing and maintaining the NCCN Guidelines. These policies are available to the public on the NCCN website. Identification of newly published research, NCCN Member Institution review, external stakeholder submissions and panel review occur on an ongoing basis with at least annual review performed for NCCN Guidelines for each disease.
For more information: www.nccn.org
April 25, 2024 
